Michael Siekman

Would Exercising March-in Rights Lower Biologic Prices?

Where Were Biologics-Related Patents Involved In BPCIA Litigation Invented?

Are Reference Product Sponsors Asserting More Patents In BPCIA Litigation?

Proposed BPCIA Reform Legislation Likely To Have Little Effect Even If Passed

FDA Platform Technology Draft Guidance Highlights Utility Of Obscure Patent Term Extension Provision